← Back to Vaccine Database

Ad26.COV2.S

Viral vector (Non-replicating) vaccine · VDDBV0033

Target & Classification

SARS-CoV-2SARS-CoV-2
Viral vector (Non-replicating) vaccine
COVID-19
ApprovedPhase 4 reached

Clinical Development

Phase 1
Phase 2
Phase 3
Approved

Clinical Trials20

Note: 1 additional source trial listed this vaccine in studies of unrelated viruses (e.g. as a comparator, adjunct, or in coadministration trials with other vaccines). Those trials are not shown here.

NCT IDPhaseDisease / Condition
NCT04509947 Phase 1COVID-19
NCT04894305 Phase 1COVID-19
NCT04436276 Phase 2COVID-19
NCT04889209 Phase 2COVID-19
NCT05109559 Phase 2COVID-19
NCT04535453 Phase 2COVID-19
NCT04765384 Phase 2COVID-19
NCT05324319 Phase 2COVID-19
NCT04505722 Phase 3COVID-19
NCT04614948 Phase 3COVID-19
NCT04838795 Phase 3COVID-19
NCT05048940 Phase 3COVID-19
NCT05047640 Phase 3COVID-19
NCT05091307 Phase 3COVID-19
NCT05142319 Phase 3COVID-19
NCT05220397 Phase 3COVID-19
NCT05030974 ApprovedCOVID-19
NCT05037266 ApprovedCOVID-19
NCT05075538 ApprovedCOVID-19
NCT02403505 Phase 1COVID-19